Novel agents in the management of pancreatic adenocarcinoma: Phase I studies

Journal of the Pancreas

Volumn 12, Issue 2, 2011, Pages 114-116

  Dimou, Anastasios T ^a   Syrigos, Konstantinos N ^b   Saif, Muhammad Wasif ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c College of Physicians and Surgeons and the Herbert Irving Cancer Center ^*  (United States)

Author keywords

Adverse effects; Clinical trials; Mitogen activated protein kinase kinases; Pancreatic neoplasms; Phase i as topic

Indexed keywords

ANTICOAGULANT AGENT; CONNECTIVE TISSUE GROWTH FACTOR; ERLOTINIB; FG 3019; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GSK 1120212; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OXALIPLATIN; PCI 27483; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; BLOOD TOXICITY; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PNEUMONIA; PROTHROMBIN TIME; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR GROWTH; UVEITIS;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; CONNECTIVE TISSUE GROWTH FACTOR; DEOXYCYTIDINE; ENZYME INHIBITORS; FACTOR VIIA; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; PANCREATIC NEOPLASMS; PYRIDONES; PYRIMIDINONES; TREATMENT OUTCOME;

EID: 79952805490     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362:1605-1617. [PMID 20427809]
2. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-1966. [PMID 17452677]
3. Kim R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer? Lancet Oncol 2011;12:8-9. [PMID 21050812]
4. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53:549-554. [PMID 2453289]
5. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007; 6:1186-1197. [PMID 17406031]
6. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28:3617-3622. [PMID 20606091]
7. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009; 27:4834-4838. [PMID 19738116]
8. Tolcher AW, Bendell JC, Patnaik A, Papadopoulos K, Bellew KM, Cox DS, Xu Y, et al. A phase Ib study of the MEK inhibitorGSK1120212 combined with gemcitabine in patients with solid tumors: Interim results. J Clin Oncol 2011; 29(Suppl. 4):Abstract 278.
9. Heestand GM, Pipas JM, Valone F, McMullen AD, Gadea P, Williams D, Zhong M, et al. A phase I trial of the monoclonal antibody FG-3019 to connective tissue growth factor (CTGF) in locally advanced or metastatic pancreatic cancer. J Clin Oncol 2011; 29(Suppl. 4):Abstract 269.
10. Ramanathan RK, Gressler V, Shah S, Loury D, Hamdy A, Khorana A. A Phase I/II study of PCI-27483, a coagulation factor VIIa (FVIIa) inhibitor in patients with advanced pancreatic cancer receiving treatment with gemcitabine. J Clin Oncol 2011; 29(Suppl. 4):Abstract 221.
11. Bloomston M, Marsh C, Walker J, Coyle W, Marx H, Tahiri S, Moran Cruz C, et al. Phase I trial of gene-mediated cytotoxic immunotherapy in combination with chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2011; 29(Suppl. 4):Abstract 195.
12. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22:4456-4462. [PMID 15483017]
13. Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, Rominger CM, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011 Jan 18. [PMID 21245089]
14. Adler SG, Schwartz S, Williams ME, Arauz-Pacheco C, Bolton WK, Lee T, Li D, et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 2010; 5:1420-1428. [PMID 20522536]
15. Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000; 11:2197-2205. [PMID11084677]
16. Chévez-Barrios P, Chintagumpala M, Mieler W, Paysse E, Boniuk M, Kozinetz C, Hurwitz MY, et al. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol 2005; 23:7927-7935. [PMID 16258092]
17. Li N, Zhou J, Weng D, Zhang C, Li L, Wang B, Song Y, et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2007; 13:5847-5854. [PMID 17908978]
18. Xu F, Li S, Li XL, Guo Y, Zou BY, Xu R, Liao H, et al. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Cancer Gene Ther 2009;16:723-730. [PMID 19363470]